9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
7 hedge funds and large institutions have $73K invested in 9 Meters Biopharma in 2017 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
46% less capital invested
Capital invested by funds: $134K → $73K (-$61K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
+$30.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.42K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$3.07K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$140 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$20K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.26K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VKH
1
Virtu KCG Holdings
New York
| $32K | +$30.7K | +220 | +200% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $18K | -$1.26K | -9 | -5% |
|
|
RJFSA
3
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| $11K | – | – | – |
|
4
Northern Trust
Chicago,
Illinois
| $6K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $4K | +$6.42K | +46 | New |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $2K | +$3.07K | +22 | New |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$20K | -84 | Closed |
|
|
TRCT
8
Tower Research Capital (TRC)
New York
| – | -$1K | -3 | Closed |
|
|
IA
9
IFP Advisors
Tampa,
Florida
| – | +$140 | +1 | New |
|
NMTR Hedge Fund Activity: Q2 2017 in Review
7 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q2 2017, worth a combined $73K — down 46% from $134K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new NMTR positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Virtu KCG Holdings, adding an estimated $30.7K. The largest seller was Citadel Advisors, exiting entirely with an estimated $20K sold.
- 7 institutional investors held 9 Meters Biopharma (NMTR) as of Q2 2017, up from 6 in Q1 2017.
- Funds reported $73K of 9 Meters Biopharma stock for Q2 2017, down 46% quarter-over-quarter.
- 3 funds opened new 9 Meters Biopharma positions in Q2 2017 and 2 closed out, a net change of +1 holder.
- The largest 9 Meters Biopharma buyer in Q2 2017 was Virtu KCG Holdings, an estimated $30.7K added.
- The largest 9 Meters Biopharma seller in Q2 2017 was Citadel Advisors, an estimated $20K sold.
Based on aggregated 13F filings for Q2 2017.